表紙
市場調査レポート

Abicipar Pegol (黄斑浮腫・黄斑変性症治療薬) :予測・市場分析

Abicipar Pegol (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 325956
出版日 ページ情報 英文 109 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
Abicipar Pegol (黄斑浮腫・黄斑変性症治療薬) :予測・市場分析 Abicipar Pegol (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023
出版日: 2014年10月31日 ページ情報: 英文 109 Pages
概要

Allergan社のAbicipar Pegolは、DARPin技術を基にした新しい長時間作用型抗VEGF治療薬です。滲出型AMD (滲出型加齢性黄斑変性症) 患者向けの治療薬として臨床開発中であり、フェーズIIIの治験は2015年第2四半期に開始される予定となっています。

当レポートでは、世界の黄斑浮腫・黄斑変性症市場について調査し、疫学、病因、症状、診断、病理学、および治療ガイドラインを含めた黄斑浮腫・黄斑変性症の概要、競合情勢の概要、製品説明、安全性、および効能プロファイルなどを含めたAbicipar Pegolの詳細情報、主要国における売上予測・売上情報などをまとめ、お届け致します。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 黄斑変性症の概要
    • 病因・病態生理学
    • 分類
    • 症状・診断
  • 黄斑浮腫の概要

第4章 疾病管理

  • 診断・治療概要
    • 黄斑浮腫の診断
    • 黄斑変性症の診断
    • 治療ガイドライン・主な処方薬
    • 臨床診療

第5章 競合評価

  • 概要

第6章 アンメットニーズ・機会

  • 概要
  • 乾燥型AMD (乾燥型加齢性黄斑変性症) の治療
    • アンメットニーズ
    • ギャップ分析
    • 機会
  • 長時間作用型抗VEGF治療薬療法
  • 滲出型AMD (滲出型加齢性黄斑変性症) 向け抗VEGF治療の効能の拡大
  • 低侵襲性製剤
  • 認識・初期の患者診断
  • AMD進行の在宅モニタリング

第7章 パイプライン評価

  • 概要
  • 臨床開発における有望薬

第8章 Abicipar pegol

  • 概要
  • 効能
  • 安全性
  • 診断・処方
  • 臨床・商業ポジショニングの可能性
  • SWOT分析
  • 予測

第9章 付録

  • 参考文献
  • 略語
  • 調査手法
  • 予測手法
  • 一次調査:KOLインタビュー
  • 一次調査:処方箋を乱発する医師の調査
  • 著者について
  • GlobalData について
  • 免責事項

図表リスト

目次
Product Code: GDHC485DFR

Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

Allergan's abicipar pegol is a novel, long-acting anti-VEGF drug that is based on the DARPin technology. It is undergoing clinical development as a potential treatment for patients with wAMD, and a Phase III clinical trial is expected to begin in Q2 2015.

Scope

  • Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Abicipar Pegol including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Abicipar Pegol for the top country from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, UK and Japan

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of Abicipar Pegol performance.
  • Obtain sales forecast for Abicipar Pegol from 2013-2023 in top 7 countries (the US, France, Germany, Italy, Spain, UK and Japan).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Related Reports

3. Disease Overview

  • 3.1. Macular Degeneration Overview
    • 3.1.1. Etiology and Pathophysiology
    • 3.1.2. Classification
    • 3.1.3. Symptoms and Diagnosis
  • 3.2. Macular Edema Overview
    • 3.2.1. Etiology and Pathophysiology
    • 3.2.2. Classification
    • 3.2.3. Symptoms and Diagnosis

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Macular Edema Diagnosis
    • 4.1.2. Macular Degeneration Diagnosis
    • 4.1.3. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.4. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Treatment for Dry AMD
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Longer-Acting Anti-VEGF Drug Therapy
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Increased Efficacy of Anti-VEGF Therapy for wAMD
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Less Invasive Drug Formulations
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Awareness and Earlier Patient Diagnosis
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. Home Monitoring of AMD Progression
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development

8. Abicipar pegol

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical and Commercial Positioning

8.6. SWOT Analysis

  • 8.7. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed ME and AMD Patients
    • 9.4.2. Percentage of Drug-Treated Patients
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Pricing of Pipeline Agents
  • 9.5. Primary Research - KOLs Interviewed for this Report
  • 9.6. Primary Research - High-Prescribers Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Therapy Area Director
    • 9.7.3. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: ARM System Classification of AMD
  • Table 2: Symptoms of AMD
  • Table 3: National and International Treatment Guidelines for ME and AMD
  • Table 4: Most Prescribed Drugs for ME and AMD in the Global Markets, 2013
  • Table 5: Leading Treatments for ME and AMD, 2014
  • Table 6: Unmet Needs and Opportunities in ME and AMD
  • Table 7: Promising Drugs in Clinical Development for ME and AMD
  • Table 8: Comparison of Drugs in Development for ME and AMD, 2014
  • Table 9: Product Profile - Abicipar pegol
  • Table 10: SWOT Analysis - Abicipar pegol, 2014
  • Table 11: Global Sales Forecast ($m) for Abicipar Pegol, 2013-2023
  • Table 12: Surveyed High-Prescribing Physicians (Non-KOLs), by Country

List of Figures

  • Figure 1: Anatomy of the Eye and Macula
  • Figure 2: Amsler Grid viewed by Patient with Normal Vision and with wAMD
  • Figure 3: Color Fundus Photographs of Dry and Wet AMD
  • Figure 4: FAF Imaging of GA
  • Figure 5: Imaging of wAMD
  • Figure 6: CMT in DME
  • Figure 7: RVOs (BRVO and CRVO) on an FA
  • Figure 8: Increased CRT in ME-RVO
  • Figure 9: ME Clinical Treatment Flowchart
  • Figure 10: AMD Clinical Treatment Flowchart
  • Figure 11: Competitive Assessment of Late-Stage Pipeline Agents in ME and AMD, 2013-2023
  • Figure 12: Abicipar Pegol's Clinical Development in wAMD and DME
  • Figure 13: Clinical and Commercial Positioning of abicipar pegol
Back to Top